StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Getting excited for the week ahead

<< Previous

Bullboard Posts

Next >>

Comment by JHendrixon Mar 21, 2021 6:43pm

150 Views

Post# 32847737

RE:RE:RE:RE:RE:Getting excited for the week ahead

Reason for excitement is Aristotle release is expected by end of Q1, Mar 31. May 17th has a different set of anticipated excitement.

People need to brace for disappointing revenue numbers. Labs use cash basis not accrual (accounts receivable) of recording revenue. Could happen that rev numbers are lower due to customers are late payers.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record